# Bloom Science, Inc.

> Bloom Science is a San Diego clinical-stage biotech translating the biology of the ketogenic diet into oral live biotherapeutics that act through the gut-immune-brain axis. Built on microbiome research licensed from UCLA and powered by its IrisRx discovery platform, the company is developing BL-001, a once-daily bacterial therapy being studied in obesity and in drug-resistant seizures from Dravet syndrome, with a pipeline reaching toward ALS and neurodegenerative disease.

- **Founded:** 2017
- **Headquarters:** San Diego, California, United States
- **Founders:** Christopher Reyes (CEO, Founder & Director), Louis Licamele (Chief Development Officer, EVP Clinical & Data Science (founding team)), Elaine Hsiao (Co-Founder & Scientific Advisor (UCLA)), Raphael Valdivia (Co-Founder & Scientific Advisor)
- **Team size:** ~16 employees
- **Products:** BL-001, IrisRx discovery platform, Neuro & metabolic pipeline
- **Notable:** Launched out of UCLA with an exclusive technology license to develop microbiome-based neurological therapies, Closed a $12M Series A led by Leaps by Bayer and the ALS Investment Fund, Built the IrisRx reverse-translation discovery platform

## Products & services

- **BL-001** — A first-in-class, orally delivered, once-daily live biotherapeutic product designed to replicate the therapeutic effects of the ketogenic diet through the microbiome. In development for weight loss in obesity and for drug-resistant seizures in Dravet syndrome and other developmental and epileptic encephalopathies.
- **IrisRx discovery platform** — A proprietary drug-discovery platform that reverse-translates proven clinical interventions to identify the compositional and functional microbiome building blocks behind them, then designs multi-pathway therapeutics using gut commensal microbes and synthetic biology.
- **Neuro & metabolic pipeline** — Preclinical and discovery programs extending the platform toward ALS, neuropsychiatric conditions, Alzheimer's disease, and other neurodegenerative and cognitive disorders.

## Achievements

- Launched out of UCLA with an exclusive technology license to develop microbiome-based neurological therapies
- Closed a $12M Series A led by Leaps by Bayer and the ALS Investment Fund
- Built the IrisRx reverse-translation discovery platform
- Advanced BL-001 into Phase 1, reporting safety, tolerability, and statistically significant weight loss
- Featured by Nature on harnessing the gut-immune-brain axis to treat disease

## Latest updates

- **2021-12** — Raised $12M Series A led by Leaps by Bayer and the ALS Investment Fund to advance its microbiome pipeline.
- **2022-01** — Profiled by Nature on the gut-immune-brain axis as a route to treating disease.
- **2023-02** — Refreshed brand and positioning around 'Revolutionizing Metabolic and Neurological Health,' expanding BL-001 into obesity alongside Dravet syndrome.

## Links

- Website: https://bloomscience.com
- LinkedIn: https://www.linkedin.com/company/bloomscience
- Twitter/X: https://twitter.com/bloomscience
- Facebook: https://facebook.com/bloomscience/

---

Profile page: https://yespress.io/bloom-science-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-10